Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice

Journal of Immunotoxicology

Volumn 9, Issue 3, 2012, Pages 275-281

  Sevko, Alexandra ^a   Kremer, Veronika ^a   Falk, Christine ^b   Umansky, Ludmila ^c   Shurin, Michael R ^d   Shurin, Galina V ^d   Umansky, Viktor ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Chemoimmunomodulation; Immature myeloid cells; Myeloid derived suppressor cells; Non cytotoxic chemotherapy; Paclitaxel; Peptide immunization; Regulatory T cells

Indexed keywords

GAMMA INTERFERON; MELANOMA ANTIGEN; PACLITAXEL; PHOSPHATE BUFFERED SALINE; TYROSINASE RELATED PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; LOW DRUG DOSE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; SUPPRESSOR CELL; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; IMMUNITY, CELLULAR; INTRAMOLECULAR OXIDOREDUCTASES; KILLER CELLS, NATURAL; MELANOMA; MELANOMA-SPECIFIC ANTIGENS; PACLITAXEL; T-LYMPHOCYTES, REGULATORY; VACCINATION;

EID: 84860518841     PISSN: 1547691X     EISSN: None     Source Type: Journal    
DOI: 10.3109/1547691X.2012.655343     Document Type: Article

References (41)

1. Avogadri, F., Merghoub, T., Maughan, M. F., Hirschhorn-Cymerman, D., Morris, J., Ritter, E., Olmsted, R., Houghton, A. N. and Wolchok, J. D. 2010. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic efect on melanoma through activation of humoral and cellular immunity. pii: e12670.
2. Beyer, M. and Schultze, J. L. 2006. Regulatory T-cells in cancer. Blood 108:804-811.
3. Elkabets, M., Ribeiro, V. S., Dinarello, C. A., Ostrand-Rosenberg, S., Di Santo, J. P., Apte, R. N. and Vosshenrich, C. A. 2010. IL-1ß regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur J Immunol 40:3347-3357.
4. Elkord, E., Alcantar-Orozco, E. M., Dovedi, S. J., Tran, D. Q., Hawkins, R. E. and Gilham, D. E. 2010. T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ter 10:1573-1586.
5. 1 and cycling peripheral blood lymphocytes and induce massive deletion of mature T-and B-cells. Cancer Res 60:1901-1907. (Pubitemid 30207650)
6. Gabrilovich, D. I. and Nagaraj, S. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162-174.
7. Genestier, L., Paillot, R., Fournel, S., Ferraro, C., Miossec, P. and Revillard, J. P. 1998. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T-cells. J Clin Invest 102:322-328. (Pubitemid 28335191)
8. Grauer, O. M., Sutmuller, R. P., van Maren, W., Jacobs, J. F., Bennink, E., Toonen, L. W., Nierkens, S. and Adema, G. J. 2008. Elimination of regulatory T-cells is essential for an efective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer 122:1794-1802. (Pubitemid 351413426)
9. Hamid, R.and Brandt, S. J. 2009. Transforming growth-interacting factor (TGIF) regulates proliferation and diferentiation of human myeloid leukemia cells. Mol Oncol 3:451-463.
10. He, Q., Li, J., Yin, W., Song, Z., Zhang, Z., Yi, T., Tang, J., Wu, D., Lu, Y., Wang, Z., Liu, D., Zhang, X., Hu, Z. and Gao, J. 2011. Low-dose paclitaxel enhances the anti-tumor efcacy of GM-CSF surface-modifed whole-tumor-cell vaccine in mouse model of prostate cancer. Cancer Immunol Immunother 60:715-730.
11. Hodi, F. S. 2006. Well-defned melanoma antigens as progression markers for melanoma: insights into diferential expression and host response based on stage. Clin Cancer Res 12:673-678. (Pubitemid 43259845)
12. Kaneno, R., Shurin, G. V., Kaneno, F. M., Naiditch, H., Luo, J.and Shurin, M. R. 2011. Chemotherapeutic agents in low non-cytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol (Dordr) 34:97-106.
13. Kaneno, R., Shurin, G. V., Tourkova, I. L. and Shurin, M. R. 2009. Chemomodulation of human dendritic cell function by anti-neoplastic agents in low noncytotoxic concentrations. J Transl Med 7:58.
14. Kubo, M., Morisaki, T., Matsumoto, K., Tasaki, A., Yamanaka, N., Nakashima, H., Kuroki, H., Nakamura, K., Nakamura, M.and Katano, M. 2005. Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production. Cancer Immunol Immunother 54:468-476. (Pubitemid 40543686)
15. Locher, C., Conforti, R., Aymeric, L., Ma, Y., Yamazaki, T., Rusakiewicz, S., Tesnière, A., Ghiringhelli, F., Apetoh, L., Morel, Y., Girard, J. P., Kroemer, G. and Zitvogel, L. 2010. Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci 1209:99-108.
16. Lu, X., Jiang, X., Liu, R., Zhao, H. and Liang, Z. 2008. Adoptive transfer of pTRP2-specifc CTLs expanding by bead-based artifcial antigen-presenting cells mediates anti-melanoma response. Cancer Lett 271:129-139.
17. Mackall, C. L. 2000. T-cell immunodefciency following cytotoxic antineoplastic therapy: a review. Stem Cells 18:10-18.
18. Mantovani, A. 2010. Te growing diversity and spectrum of action of myeloid-derived suppressor cells. Eur J Immunol 40:3317-3320.
19. Milich, D. R., McLachlan, A., Stahl, S., Wingfeld, P., Tornton, G. B., Hughes, J. L. and Jones, J. E. 1988. Comparative immunogenicity of hepatitis B virus core and E antigens. J Immunol 141:3617-3624.
20. Naiditch, H., Shurin, M. R. and Shurin, G. V. 2011. Targeting myeloid regulatory cells in cancer by chemotherapeutic agents. Immunol Res 50:276-285.
21. Orlow, S. J., Zhou, B. K., Chakraborty, A. K., Drucker, M., Pifko-Hirst, S.and Pawelek, J. M. 1994. High-molecular-weight forms of tyrosinase and the tyrosinase-related proteins: evidence for a melanogenic complex. J Invest Dermatol 103:196-201. (Pubitemid 24234607)
22. Ostrand-Rosenberg, S. and Sinha, P. 2009. Myeloid-derived suppressor cells: linking infammation and cancer. J Immunol 182:4499-4506.
23. Parkhurst, M. R., Fitzgerald, E. B., Southwood, S., Sette, A., Rosenberg, S. A. and Kawakami, Y. 1998. Identifcation of a shared HLA-A 0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 58:4895-4901. (Pubitemid 28503687)
24. Pavelko, K. D., Hansen, M. J.and Pease, L. R. 2009. CTL activation using the natural low-afnity epitope 222-229 from tyrosinase-related protein 1 leads to tumor rejection. Cancer Res 69:3114-3120.
25. Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S. and Bronte, V. 2010. Myeloid-derived suppressor cell heterogeneity and subset defnition. Curr Opin Immunol 22:238-244.
26. Rass, K.and Hassel, J. C. 2009. Chemotherapeutics, chemoresistance and the management of melanoma. G Ital Dermatol Venereol 144:61-78.
27. Rook, G. A.and Dalgleish, A. 2011. Infection, immunoregulation, and cancer. Immunol Rev 240:141-159.
28. Rozner, A. E., Dambaeva, S. V., Drenzek, J. G., Durning, M.and Golos, T. G. 2009. Generation of macrophages from peripheral blood monocytes in the rhesus monkey. J Immunol Methods 351:36-40.
29. Shurin, G. V., Tourkova, I. L. and Shurin, M. R. 2008. Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells. J Immunother 31:491-499.
30. Shurin, G. V., Tourkova, I. L., Kaneno, R. and Shurin, M. R. 2009. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 183:137-144.
31. Singh, V., Ji, Q., Feigenbaum, L., Leighty, R. M. and Hurwitz, A. A. 2009. Melanoma progression despite infltration by in vivo-primed TRP-2-specifc T cells. J Immunother 32:129-139.
32. Tormo, D., Ferrer, A., Bosch, P., Gafal, E., Basner-Tschakarjan, E., Wenzel, J. and Tüting, T. 2006. Terapeutic efcacy of antigen-specifc vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice. Cancer Res 66:5427-5435. (Pubitemid 43844970)
33. Travlos, G. S. 2006. Normal structure, function, and histology of the bone marrow. Toxicol Pathol 34:548-565. (Pubitemid 44652217)
34. Umansky, V., Abschuetz, O., Osen, W., Ramacher, M., Zhao, F., Kato, M.and Schadendorf, D. 2008. Melanoma-specifc memory T-cells are functionally active in Ret transgenic mice without macroscopic tumors. Cancer Res 68:9451-9458.
35. Wang, R. F., Appella, E., Kawakami, Y., Kang, X. and Rosenberg, S. A. 1996. Identifcation of TRP-2 as a human tumor antigen recognized by cytotoxic T-lymphocytes. J Exp Med 184:2207-2216. (Pubitemid 27023721)
36. Wessels, I., Fleischer, D., Rink, L.and Uciechowski, P. 2010. Changes in chromatin structure and methylation of the human interleukin-1beta gene during monopoiesis. Immunology 130:410-417.
37. Whiteside, T. L. 2009. Tricks tumors use to escape from immune control. Oral Oncol 45:e119-e123.
38. Youn, J. I. and Gabrilovich, D. I. 2010. Te biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40:2969-2975.
39. Zhong, H., Han, B., Tourkova, I. L., Lokshin, A., Rosenbloom, A., Shurin, M. R. and Shurin, G. V. 2007. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res 13:5455-5462. (Pubitemid 47510373)
40. Zitvogel, L., Kepp, O. and Kroemer, G. 2011. Immune parameters afecting the efcacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151-160.
41. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6:295-307.